MiNK Therapeutics INKT
NASDAQ INKT
$12.44 -0.29 (-2.28%)
At close: Oct 2, 2026 · 4:00 PM EDT

MiNK Therapeutics (INKT) Gains from Sales and Divestitures (2025)

Updated

MiNK Therapeutics (INKT) posted Gains from Sales and Divestitures of -$509.00 for Q4 2025.

Analysis

MiNK Therapeutics (INKT) Gains from Sales and Divestitures (2025) Analysis & Trends

For FY2025, MiNK Therapeutics' Gains from Sales and Divestitures came in at -$169,800.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 MiNK Therapeutics 63.40 Mn 63.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -509.00
Sep 30, 2025 -2,188.00
API Access

MiNK Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=INKT&period=max&api_key=YOUR_API_KEY